Key View

• Stada Arzneimittel reported a notable uptick in Group revenues in FY19, providing a solid base from which to expand in FY20.
• Biosimilars remain an under-developed market for Stada, but sales of epoetin zeta expanded rapidly in FY19 to become the top-selling product in the Generics segment. Biosimilar sales are becoming increasingly

Key View

• At Fitch Solutions, we have cut our 2020 real GDP growth forecast for Germany to account for rising headwinds from the Covid-19 (coronavirus) outbreak. 
• We now expect Germany to grow by 0.8% in 2020, down from 1.1% previously, with risks to our forecasts heavily skewed towards lower growth. We have kept our 2021 growth projection at 1

Key View

• May Purchasing Managers’ Index (PMI) data supports our relatively bullish outlook for Germany.
• We at Fitch Solutions expect German real GDP to grow by 1.2% in 2019 and 1.4% in 2020. Our balance of risks, however, will remain tilted to the downside.
• Record-low unemployment will continue to boost activity in the services sector, while

Key View

• We at Fitch Solutions have used a vector autoregression (VAR) model to assess the impact of changes in bond yields on growth using 20 years of historical data across several developed markets.
• According to our model, the decline in bond yields could help add up to 22.0bps to US GDP over coming quarters; up to 2.1bps and 1.9bps to

Key View

• Boehringer Ingelheim is expanding its presence in the oncology research arena through acquisitions and agreements, and is likely to create a notable oncology portfolio through a series of deals.
• Drug delivery is a key theme is oncology drug research, currently being employed to extend revenue generating life for ageing drugs, and will